Legal Representation
Attorney
Maury M. Tepper, III
USPTO Deadlines
Next Deadline
1363 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-04-25)
Due Date
April 25, 2029
Grace Period Ends
October 25, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
36 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 25, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Apr 25, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 23, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Mar 22, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Mar 20, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Mar 14, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Mar 14, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Mar 7, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 6, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Mar 3, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Feb 17, 2023 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Feb 17, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 26, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 24, 2022 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Aug 24, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Aug 24, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 19, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 17, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Feb 17, 2022 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Feb 17, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 28, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 26, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Aug 26, 2021 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 26, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 23, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 19, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 19, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 19, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 8, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 14, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 14, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 24, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 5, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 3, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 5, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 28, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
First Use Anywhere:
Mar 11, 2023
First Use in Commerce:
Mar 11, 2023
Classification
International Classes
005